Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
New York hedge fund approached by Warner shareholder to buy CNN
...
Read moreDetailsHome » FDA approves Johnson & Johnsons nasal spray for depression as standalone treatment
Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
...
Read moreDetails